The clinical-stage biopharmaceutical company ( SNNA ) enjoyed an incredible rally and skyrocketed by as much as 76% on Monday. There was no material news with regards to the company that could have been a catalyst. It is perhaps more intriguing since on September 17 it had emerged that the company had filed for Chapter 11 bankruptcy. This was done in order to...
One of the penny stocks to watch due to its recent performance is that of Capricor Therapeutics Inc (CAPR Stock Report). Back on September 24, the company had been granted a meeting by the United States Food and Drug Administration. " Shares gained as much as 20% as Capricor stock started the week with a bang. It is one of the biotech penny stocks that have...
"Since August 21st, Bellicum’s stock has made a very strong rally on the back of news releases. The price of the biotech penny stock is up nearly over 30% since the beginning of the month. This gain and volume increase came initially following the company’s $140 million public offering on the 21st. Bellicum is also participating in 3 healthcare investor...
Aveo recently announced that the Tivozanib drug , in its second analysis, showed an improved survival hazard ratio. This penny stock news prompted the company’s stock to fly over 60% from Monday’s opening bell to Tuesday’s premarket high of $1.10. But just as quickly as it jumped, AVEO pulled back aggressively during the last 30 minutes of trading on September...
Indeed! Strong Buy since $13.7 made public worldwide
After breaking to higher ground a week ago on enormous volume, shares of ARDELYX INC - NASDAQ: ARDX find themselves in constructive consolidation mode digesting the recent run on lower volume as we can observe from the Daily chart above. With the stock trading well above its 20/50 and 200 DMA's on the Daily timeframe, the short-term technical posture of ARDX ...
"On Tuesday, the company earned attention from analysts at H.C. Wainwright. The research firm initiated coverage on MRNS stock. It gave the company a “BUY” rating as well as a price target of $5 per share. This was the 3rd analyst firm to initiate coverage on the stock this year. Previous to H.C. Wainwright, Jefferies and Leerink Swann both initiated coverage with...
ABEO stock has been beaten down for much of 2019. It had declined by as much as 80% since the beginning of the year. It went on to emerge as one of the biggest gainers in the market yesterday. The company announced that it was going to explore options that could unlock value for the shareholders. It stated that even an outright sale or a takeover is being...
What are the thoughts here? News? -NOPE...pure momentum today? Biggest volume it's had since the big drop day so what can explain this move? "Intec Pharma Ltd. is a biotechnology company that creates drugs using its Accordion Pill technology. This technology is designed to improve the safety of drugs when taken orally. The company currently has 5 treatments in...
Mallinckrodt named the best biotech stocks to sell short in a decade
Will have a serious drop soon. But it's all the set up for the bullish BAT pattern guys.
Final Data from Robarts study coming September, in Spain. To learn more about TAEUS, click here . Company ran by ex-GE executives. TAM is in the Billions of Dollars $$. Low float. Recently broke long-term down trend. Daily, Weekly, Monthly charts #BULLISH. Fibonacci convergence at 618 fib (projection) into September time frame. Follow me on twitter and...
Technicals analysis WEEKLY Davita broke a downtrend channel, and is now in a consolidation above the 200SMA. (Bull) 50SMA is now crossing above the 200SMA. (Bull) OBV and RSI show divergence, as they have moved in oposite directions since early August. (Short). However... on a daily chart , we see a decent uptrend since early June. Headlines /...
BUY CODX = 1.1$ STOP=0.7$ TARGET1=2.9$ R=4 TARGET2=3.8$ R=7 TARGET3=5.1$ R=10 Chart 1 month big big level and base = 0.8$ to 1.1$ NEXT level 3.0$ usd CODX is setting up to be a major player in the extremely “Profitable” $100Bil Biotechnology sector focusing on “Cancer Detection” using its patented CoPrimer™ technology with applications in Liquid Biopsy...
Earnings/News Co's lead cancer therapy, trilaciclib, gets FDA's "breakthrough therapy" status, which is meant to speed up review of drugs that treat life-threatening conditions GTHX says it will present new data on three of its drugs, including trilaciclib, at an upcoming conference in September FDA's move is a recognition that clinical data presented...
KRYS has hit FIB golden ratio resistance and peaked out on 5th wave. Looking for pullback to low $40's then we'll find out if it wants to fill the gap. Please like/ comment so I can continue looking for awesome trades. Thank you in advance. Message me if your interested in learning more on pattern analysis . Follow trend, Buy low sell high!! Follow me on...
This trade brings opportunity for investors looking for a a company with great fundamentals and nice risk/reward potential into end of year. As the chart shows (blue arrows) I am awaiting a buying opp around the blue trend line. From current stock price, potential risk/reward around 3.5 : 1 downside risk: $1.39 upside reward: $3.50-$5 Recent selloff after...
After a recent selloff in mid June 2019, Stock price went from from $6.70 down to $3.44. Cala looks to have established a double bottom. New strong uptrend suggests it has potentially capitulated from the selloff making these levels very attractive for any investors who are sidelined and looking for a good technical/ fundamental trade in biotech. Cala looks to be...